UroGen settles JELMYTO patent litigation with Teva
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Oracle raises full year profit guidance, stock rises after hours
- Oil surges 6%, Brent and US crude both surpass $100 on more tanker attacks
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- White House copper tariff plan stalls amid affordability concerns, sources say
- Micron's Taiwan workers to get rewards worth up to 68 months of pay
- Crude Inventory 0.4M Barrels Last Week - EIA
- Vertiv shares drop on acquisition skepticism, AI pullback
- S&P 500, Dow futures attempt recovery ahead of inflation report
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
June 2, 2026 8:00 AM EDTAgreement reinforces the value of UroGens innovation and reflects the strength of the Companys intellectual property portfolioTeva will be granted a non-exclusive license to sell its generic version of JELMYTO beginning on September 15, 2030, if approved by the FDA
PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has entered into a settlement and license agreement (the Agreement) with Teva... More
